Top Page
LifeTech Scientific Corporation
(1302)
LifeTech Scientific Corporation (1302) vs. iShares MSCI Hong Kong ETF (EWH)
LifeTech Scientific Corporation Business Overview & Revenue Model
LifeTech Scientific Corporation Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33B | 1.30B | 1.27B | 1.10B | 925.33M | 642.30M |
| Gross Profit | 963.81M | 981.43M | 995.64M | 873.93M | 747.53M | 513.14M |
| EBITDA | 134.22M | 271.87M | 253.46M | 445.78M | 397.59M | 314.14M |
| Net Income | 71.91M | 222.39M | 263.24M | 325.34M | 292.47M | 216.09M |
Balance Sheet | ||||||
| Total Assets | 5.33B | 4.90B | 4.70B | 3.69B | 3.18B | 2.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 1.18B | 1.18B | 833.79M | 1.48B | 1.14B |
| Total Debt | 3.91M | 4.98M | 9.30M | 9.67M | 15.67M | 185.98M |
| Total Liabilities | 1.60B | 1.42B | 1.37B | 769.05M | 653.61M | 596.06M |
| Stockholders Equity | 3.77B | 3.49B | 3.37B | 2.90B | 2.50B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | 572.83M | 38.46M | 125.36M | 52.84M | 145.57M | 180.15M |
| Operating Cash Flow | 610.06M | 321.46M | 418.05M | 388.32M | 488.85M | 338.53M |
| Investing Cash Flow | -566.23M | -517.53M | -453.88M | -458.47M | -86.76M | -341.63M |
| Financing Cash Flow | -92.84M | -116.97M | 182.71M | -215.20M | -256.38M | 674.66M |
LifeTech Scientific Corporation Technical Analysis
LifeTech Scientific Corporation Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$6.89B | 31.91 | 11.79% | 1.50% | -5.18% | -9.69% | |
58 Neutral | HK$8.49B | 46.07 | 4.99% | 0.48% | 35.01% | 483.73% | |
57 Neutral | HK$7.90B | 102.81 | 1.98% | ― | 3.42% | -70.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$22.52B | -17.03 | -24.77% | ― | -1.04% | 60.66% | |
43 Neutral | HK$5.03B | 359.09 | 0.22% | ― | -4.38% | ― |
LifeTech Scientific Corporation Corporate Events
LifeTech Scientific Corporation announced the resignation of independent non-executive director Wang Wansong, who is stepping down effective 26 January 2026 after serving more than nine years, in order to comply with Hong Kong Stock Exchange requirements on long-serving independent directors. His departure leaves the company temporarily below the minimum number of independent non-executive directors and committee members required under the Listing Rules, prompting the board to commit to appointing a suitable replacement within three months, while simultaneously naming existing independent director Chen Dongxia as chair of the remuneration committee to ensure continuity in key board functions.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation has announced the current composition of its board of directors, detailing five executive directors, one non-executive director and two independent non-executive directors, led by Chairman and Chief Executive Officer Xie Yuehui. The company also confirmed the structure of its three key board committees—Audit, Remuneration and Nomination—specifying the directors chairing and serving on each, underscoring its emphasis on corporate governance and regulatory compliance for stakeholders.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific has received confirmation from China’s National Medical Products Administration that its Concave Supra-arch Branched Stent-Graft System has been admitted into the special examination and approval procedure for innovative medical devices. Jointly developed with Fuwai Hospital’s Professor Shu Chang, the device is described as the world’s first integrated triple-branched reconstruction solution for complex aortic arch diseases, targeting aneurysms and penetrating ulcers with a minimally invasive approach that addresses long-standing anatomical and technical challenges in this high-risk field. Early clinical data from a First-in-Man feasibility study and ongoing multicenter registration trial show high technical success, low short-term mortality and stroke rates, and strong safety and efficacy indicators, positioning the product as a potentially significant advance in vascular surgery and reinforcing LifeTech’s standing as an innovator in China’s cardiovascular device market.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation announced that its independently developed G-iliac™ Pro iliac artery stent graft system has received official registration approval from China’s National Medical Products Administration, clearing the way for its commercialization in the domestic market. Designed for the endovascular treatment of abdominal aortic aneurysms with associated iliac artery aneurysms or isolated common iliac artery aneurysms, the upgraded device builds on the company’s earlier G-iliac™ iliac branch technology and integrates the flexible SilverFlow™ Pro stent graft to preserve internal iliac artery blood flow while reducing complications linked to traditional embolization. Featuring a low-profile, ergonomically designed delivery system with advanced hydrophilic coating and improved navigation and positioning capabilities, G-iliac™ Pro strengthens LifeTech’s product lineup in full aortic minimally invasive treatment, enhances its competitive position in China’s endovascular reconstruction market, and supports the broader industry shift toward more systematic, standardized and precise management of complex aortic disease.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation has entered into an agreement to purchase 230,000,000 shares from a substantial shareholder as part of its Share Award Scheme. This transaction, which involves a connected person under the Listing Rules, is valued at HK$437,000,000 and represents approximately 4.97% of the company’s issued share capital. The purchase is made at a slight discount to recent average closing prices, and while it requires reporting and announcement, it is exempt from circular and independent shareholder approval requirements.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation has announced significant changes in its board of directors and committee compositions, effective November 21, 2025. Notably, Ms. Ruan Xingmei and Mr. Liang Hsien Tse Joseph have resigned from their respective director roles, while new appointments include Ms. Wu Liping, Mr. Fang Yu, and Ms. Feng Xiaoling as Executive Directors, and Ms. Chen Dongxia as an Independent Non-executive Director. These changes are part of the company’s strategic adjustments to enhance its governance structure, with Ms. Ruan and Mr. Liang continuing to contribute in other capacities, ensuring a smooth transition and sustained operational stability.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation has announced the composition of its board of directors and the establishment of three board committees: Audit, Remuneration, and Nomination. This organizational update reflects the company’s commitment to robust corporate governance, potentially enhancing its strategic decision-making and operational efficiency.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation announced that its G-Branch™ thoracoabdominal artery stent graft system has received official registration approval from the China National Medical Products Administration. This device, designed for the treatment of complex thoracoabdominal aortic aneurysms, offers a less invasive alternative to traditional surgery, which is associated with high risks and complications. The product’s innovative design and successful clinical trials highlight LifeTech’s commitment to advancing endovascular treatment options, potentially impacting the treatment landscape for aortic aneurysms in China.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.